Skip to content
AnalystLens

IDEXX LaboratoriesIDXX

Legal name
IDEXX Laboratories Inc.
Sector
Other
Industry
In Vitro & In Vivo Diagnostic Substances
Exchange
Nasdaq

Stock Price $IDXX

You are here#29 of 59 in Healthcare by market cap

Filing record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  1. $4.30B
YoY changeLargest recent move+18.8%in FY21Latest +10.4%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →

IDEXX Laboratories Financial Overview 2021–2025

Updated Nov 3, 2026

IDEXX Laboratories expanded its operating income by 20.5% to $1.36 billiona in FY2025, proving the deep pricing power embedded in its veterinary diagnostics ecosystem. The core investment thesis relies on a sticky, recurring revenue model built around essential companion animal healthcare that heavily insulates the business from macroeconomic turbulence. Because advanced diagnostics and laboratory consumables are critical for daily veterinary clinic operations, IDEXX consistently passes along price increases to offset inflation while driving sustained profitability.

This predictable demand allowed total revenue to grow from $3.22 billion in FY2021 to $4.30 billionb in FY2025. The Companion Animal Group anchors this trajectory, generating $3.95 billion in FY2025 as recurring diagnostic revenues regularly accounted for roughly 80% of the consolidated top line. These high-margin recurring streams fundamentally shifted the underlying profitability of the business, pushing the company's gross profit margin from 59.5% in FY2022 to 61.8% in FY2025. Management systematically directed the resulting cash flow toward shareholder returns, deploying $837.0 million for stock repurchases during FY2024 alone.

Investors have assigned a steep premium to this operational consistency. At the close of FY2025, the market rewarded IDEXX with a $53.9 billionc market capitalization, and the stock traded at $676.53. This priced the company at a demanding 51.7x multiple against its $13.08 earnings per share for the year, reflecting high market confidence in its ongoing ability to extract highly predictable cash flows from the global pet healthcare sector.

Recent Developments (Q1 and Q2 2026)

Q1 and Q2 2026 showed double-digit growth that cooled through the half. Revenue rose 14% to $1.14 billiond in Q1 2026, then 10% to $1.22 billion in Q2 2026. Gross margin widened to 64.0% in Q2 2026, and operating margin reached 35.0%. Management raised 2026 EPS guidance to $14.69–$14.94, though part of the lift came from share-based compensation benefits. CEO Jay Mazelsky is transitioning out of his role. Shareholders also approved a three-year declassification of the board in May 2026.

Bull case: recurring diagnostics grew 10% organically in Q2 2026, and $693 millione of buybacks in the half came at an average $592 per share. Bear case: capital instrument revenue fell 19%, and growth is slowing. At 45.0x earnings as of the August 3, 2026 filing date, the stock still carries a premium multiple, and that reading is not today's price.

What to watch: CEO succession and the August 13 Investor Day targets; whether organic growth holds near 9% against the raised 2026 guidance

Recent SEC Filings

  1. 8-KIDEXX Laboratories 8-K Report, Financial Results (Nov 2, 2026)IDEXX Laboratories, Inc. (IDXX) announced robust financial results for the third quarter ended September 30, 2026. The company reported a 10% increase in revenue on both a reported and organic basis, reaching $1,214 million. This growth was primarily driven by the Companion Animal Group (CAG) segment, which saw an 11% increase in recurring revenue, signaling strong performance in its core diagnostics and consumables offerings. Earnings per diluted share (EPS) also showed significant improvement, rising 18% year-over-year to $4.01. The company demonstrated its confidence in continued success by raising its full-year 2026 guidance for both revenue and EPS. Revenue guidance was increased to a range of $4,741 million to $4,767 million, with the midpoint reflecting a $32 million increase. The EPS outlook was also raised to $14.96 - $15.16. This positive outlook is supported by strong operational execution, benefits from IDEXX's innovations, and strategic acquisitions like CoVet, which is expected to enhance veterinary team productivity.
  2. 8-KIDEXX Laboratories 8-K Report, Financial Results (Aug 4, 2026)IDEXX Laboratories reported second quarter 2026 results on August 4, 2026, with revenue of $1,217 million, up 10% as reported and 9% organic. Growth was led by Companion Animal Group (CAG) at 9% and CAG Diagnostics recurring revenue, which rose 11% as reported and 10% organic, with International up 12% organic and U.S. up 10%. Management attributed the strength to volume-driven utilization, net customer expansion, and the growing premium instrument installed base, now 11% larger. Water grew 15% as reported and 13% organic, and LPD grew 11% as reported and 9% organic. Profitability improved meaningfully. Gross margin rose 140 basis points to 64.0%, and operating margin rose 140 basis points to 35.0% as reported (110 basis points comparable). Diluted EPS was $4.27, up 18% as reported and 15% comparable. Note that EPS included $0.14 of share-based compensation tax benefits and $0.06 of currency benefit, so comparable EPS of $4.07 is the cleaner run-rate measure. Operating expenses grew 10%, reflecting investments in commercial capabilities, innovation, and IT. Full-year 2026 guidance was modestly raised. Revenue is now expected at $4,700 million to $4,745 million, a $5 million increase at the midpoint after a $15 million FX headwind. EPS guidance rose to $14.69 to $14.94 from $14.45 to $14.90 at the prior midpoint, though a meaningful portion of the increase reflects share-based compensation benefits rather than operations. Management also reported strong cash generation, with six-month free cash flow of $557 million, and continued share repurchases of about $693 million in the open market during the first half.
  3. 8-KIDEXX Laboratories 8-K Report, Bylaw Amendment (May 15, 2026)IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 15, 2026, detailing significant corporate governance changes approved by shareholders at the May 12, 2026 annual meeting. The primary focus is the amendment to the Certificate of Incorporation and By-Laws to declassify the Board of Directors over a three-year period, with all directors to be elected annually starting in 2029. This move enhances shareholder oversight and aligns with modern corporate governance trends, making the board more directly accountable to shareholders. Furthermore, shareholders approved amendments granting a right to call a special meeting to those holding at least 25% of the company's capital stock continuously for at least one year. This provides a critical mechanism for shareholders to address urgent matters outside of the regular annual meeting schedule, increasing their influence and ability to effect change. The report also confirms the ratification of PricewaterhouseCoopers LLP as the independent auditor and the advisory approval of executive compensation, alongside the election of three Class II directors.
  4. 8-KIDEXX Laboratories 8-K Report, Financial Results (May 5, 2026)IDEXX Laboratories reported first-quarter 2026 results on May 5, 2026, with revenue of $1,141 million, up 14% as reported and 11% organic. Growth was led by Companion Animal Group (CAG), which grew 15% as reported and 12% organic, and CAG Diagnostics recurring revenue, which grew 14% reported and 11% organic. International recurring revenue grew 21% reported and 12% organic, while U.S. recurring revenue grew 11%, which management says outpaced sector growth. Management attributed the U.S. strength partly to a modest easing of clinical visit pressure and higher diagnostic frequency. Reported diluted EPS was $3.47, up 17% (15% on a comparable basis). Operating margin was 31.8%, up 10 bps as reported and 100 bps on a comparable basis, though operating expenses rose 17% as reported, reflecting commercial, R&D, and software investment. Gross margin improved 90 bps to 63.4%. Management raised 2026 guidance. Revenue is now $4,675-$4,760 million (8.6%-10.6% reported growth, 7.7%-9.7% organic), up about $42 million at the midpoint. The EPS outlook rose to $14.45-$14.90, with the midpoint up $0.13 from operations and $0.05 from FX, partly offset by a $0.05 loss on an equity investment. The reported operating margin outlook is 32.1%-32.5%. Foreign currency is a meaningful tailwind, adding about 0.9% to revenue growth and about $0.27 to EPS for 2026. CEO Jay Mazelsky is transitioning out of the role, with Mike Erickson named as the successor partner; the filing does not detail the leadership change beyond the release's comments. For investors, the quarter shows broad-based double-digit organic growth, driven by IDEXX VetLab consumables (15% organic), premium instrument installed base growth (12%), and early adoption of the IDEXX inVue Dx analyzer (about 1,100 placements). The main watch items are the CEO transition, the pace of U.S. clinical visit recovery, operating expense growth that outpaces revenue, and the rising use of debt to fund buybacks, with the line of credit increasing to $530 million from $398 million at year-end 2025.
  5. 8-KIDEXX Laboratories 8-K Report, Executive Changes (Mar 26, 2026)IDEXX Laboratories, Inc. (IDXX) filed an 8-K on March 26, 2026, to report the departure of Dr. Nimrata Hunt, Executive Vice President of Global Strategy and Commercial, effective April 13, 2026. This departure was a mutual agreement, and Dr. Hunt will provide advisory services until July 13, 2026. The company has entered into a separation agreement that outlines the terms of her exit and advisory role. Investors should note the financial implications of Dr. Hunt's departure, including a separation package totaling approximately $2.24 million in salary continuation and target bonuses, along with COBRA premium costs, transition assistance, and tax/financial planning reimbursements. The company is classifying this as a termination without cause. The agreement also includes standard clauses like general release of claims, non-disparagement, and ongoing adherence to restrictive covenants. This filing primarily addresses a significant executive transition and associated costs.
View all 8-K filings →